Member Info for B2HS2L

..and found I'm about to break even, - thanks mainly to shares available at 32p!

Haven't seen many of these lately, but good luck all. 🚀🚀🚀🚀🚀🚀🚀

21:34

'..We are in multiple conversations across multiple assets.

The data in phase 1B does continue to mature which is strengthening Avacta's position.

On timings I can't give definitive answers....We have number of touch points with a number of partners coming up.'

Only one agreement?

IMO more than one set of discussions would be the most likely scenario.

Https://www.lse.co.uk/ShareBrokerTips.html?shareprice=AVCT&share=Avacta-Group

Peel Hunt Buy recommendation. New Target 99p.

'This company is really starting to deliver the goods.' 😆🤣😂

sp = 57p. We ain't seen nothing yet.

I asked Grok the date of the WHO assigning the name 'faridoxorubicin' to AVA6000.

The response was 100% rubbish.

Still need to be wary of AI search validity.

Basically no progress on partnering and licensces deal.

Should read no publicised progress on partnering and licenses deal.

Yulii Bogatyrenko still Advisor, Business Development on the website.

SB still CBO.

No change there then.

..and that scanned every 12wks, the patients next scan was due in September.

Hoping to see a confirmed Partial Response to AVA6000 phase 1b treatment.

An item in the business update perhaps..

In deed it's a safety trial.

02.07.2025 - Shaun Chilton - 'We are also delighted to see initial signs of efficacy in both phase 1b indications.'

So presumably the chairman would be 'delighted' by a confirmed PR in the same trial.

There's a near term possibility of an SGC unconfirmed partial response becoming a second confirmed partial response post patient scanning.

The prospect of an associated boost to the 'efficacy' of AVA6000 in a phase 1 safety trial is likely close at hand.

On this occasion I suggest that

'Clearly it works but the opaqueness as to how well is imo revealing'

is not meaningful prior to this news.

It fact at this juncture it's total FUD.

I'm sure you will be joining us all in congratulating the company should this news be published soon.

Thanks for a detailed explanation BV.

I feel like I created and posted an examination answer, and then realised the question was not present in the exam paper.

AvctIPmatters

Avacta patent 18 Sep 2025 13:21

FYI Courtesy of stonks :

"Global #AVCT patent application published this morning, filed back in March - Polypeptides and methods for detecting and quantifying small molecules "

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025191078&_cid=P10-MFPANN-29543-1

++++

Source: 18.11.2024 - https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/

The above Avacta patent is aimed at improving the capabilities of AVA7100 technology.

AffDCs: engineered to be better than ADCs

With focus on *'small molecules'* -

The properties of Affimer proteins that confer advantages over mAbs provide AffDCs with a similar potential edge over ADCs (antibody-drug conjugates).

ADCs have become established anticancer therapeutics and have a unique mechanism of action that combines targeted therapy (via mAbs) with chemotherapy (via small molecules).

This same mechanism can be used by AffDCs; however, as they are *smaller in size* and designed to increase further the specificity of payload delivery and potentially also treat patients with low tumour FAP expression though the bystander effect (ie killing of both antigen-positive and antigen-negative tumour cells), this translates into several benefits over ADCs

++++

All 4 named inventors of this patent have left Avacta now, leaving Wetherby in early/mid 2024 according to Linkedin.

Long time since we saw a rise so large, over such a small timescale 👀

You had me @ 'You talk a load of BS'

Sp rise evident since 9 am,

News perhaps later today.

...this is a BB for an exchange of views.

I have been largely correct in my analysis of how to interpret the various data releases and what likely effect that would have on the SP.

Being right does not make me bad.

Being right does not make me bad.

This is just some of where I swam against the crowd here.

I highlighted the window for the LFT would close very quickly.

I highlighted that MM was potentially disingenuous.

I said the interviews with Paul Hill were scripted and therefore not to put much store by.

I said AS's statements were subjective and not objective and that was deliberate, casting doubt on test results.

I foretold about delays and the knock effects to funding.

I forewarned about cash raises coming.

It's all ME, ME & ME. - You leave an open goal every time you post this stuff.

Get yourself fixed.

Do any of my posts manipulate you? 🤔

https://www.psychologytoday.com/gb/blog/communication-success/202007/8-signs-of-a-narcissistic-communicator

FWIW, these website pages fail the 'diagnostic' word check, and will require updating, should you choose to report.

https://avacta.com/investors/key-information/

https://avacta.com/investors/corporate-governance/ which has the following footer:

05 June 2025 - *This page is updated annually after the publication of the Annual Report & Accounts, however:

Now we have sold Coris, and do not have a diagnostics division, they may want to reconsider an update.

+++

I asked Karen Harrison if she was performing the comms role post Vinegrad, after her name appeared on the bottom of an RNS.

She passed my query to a minion who referred me it ICR.

I replied that was the reason I had written to Karen, because I had never had the courtesy of a response from ICR, but no further comms ensued.

Assume Avacta is paying for an ICR service level agreement that doesn't meet the shareholders needs.

FWIW - https://www.esmo.org/meeting-calendar/esmo-congress-2025/abstracts

Contains

Presentation and publication of accepted abstracts

The ESMO Congress 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

*Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.

*Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.

*Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.

*Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend the Congress in person to represent their work. Preparation of an e-Poster file is also mandatory for inclusion in the Congress Virtual Platform and onsite digital screens.

*E-Poster – Electronic poster in PDF format for inclusion in the Congress Virtual Platform and onsite digital screens. Presenting authors of ePosters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.

LO - That link provides 'Abstract submission is now closed', confirmed by dates stated'.